WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Angie Harmon sue Instacart, former shopper who shot and killed her dogSyria to develop renewable energy projects to resolve electricity shortage: ministerPair of late 3Leonardo DiCaprio's girlfriend Vittoria Ceretti, 25, oils up for a racy Marc Jacobs campaignNational political themes will lead off the campaign for Pennsylvania's next attorney generalChina's Swap Connect further enhanced to promote financial opening upArgentina and Messi will play 2 warmFormer Connecticut budget official arrested, pleads not guilty to bribery and extortion chargesJeremy Wells leads the way for club pros at PGA ChampionshipFormer Connecticut budget official arrested, pleads not guilty to bribery and extortion charges
2.1897s , 6500.84375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Capsule news portal